The Foundation: Lifestyle First
The WHO's new guidance places overwhelming emphasis on what it calls 'multimodal lifestyle programmes'. This is the undisputed starting point for all children and adolescents living with obesity. The recommendations strongly advocate for structured interventions
that focus on diet, physical activity, and behavioural changes. This isn't about a one-size-fits-all diet or exercise plan. Instead, care should be 'person-centred', taking into account the individual’s age, health, and cultural context, with strong family involvement. The goal extends beyond just weight loss to encompass overall health, mental well-being, and long-term quality of life. The WHO makes it clear that the foundation of effective care is not a prescription, but comprehensive support that builds sustainable healthy habits.
A Clear Line on Age
A crucial aspect of the guidelines is the strict age distinction. For children under 10 years old, the WHO does not recommend pharmacological treatments, bariatric surgery, or weight-loss devices. The recommendation against using drugs in this younger age group is 'strong', citing a lack of evidence on the benefits and potential for adverse events during critical developmental years. For adolescents aged 10 to 19, the door to medication is not completely closed, but it is only slightly ajar. This clear age-based boundary underscores the organization's cautious approach, prioritizing safety and the need for more long-term data before endorsing powerful drugs for younger children.
Drugs as a Conditional Last Resort
For teenagers aged 10 and over, the WHO states that approved medicines may be considered, but only under very specific conditions. Pharmacotherapy is positioned as a secondary option, to be explored only after a supervised, comprehensive lifestyle program has not produced the desired results. The guidelines do not endorse any specific drug, though much of the current discussion revolves around GLP-1 agonists like semaglutide and liraglutide. Even when considered, the decision must involve a team of specialists and a close evaluation of the adolescent's physical and psychological maturity. This 'conditional recommendation' highlights that drugs are not a primary solution but a tool for specific, challenging cases where other methods have been insufficient.
The Reasons for Caution
The WHO's cautious stance stems from significant unanswered questions about the long-term impact of these powerful medications on young people. The clinical trials reviewed were relatively short, mostly lasting between three and 16 months, leaving a gap in understanding the effects over many years. Concerns include potential side effects like nausea, vomiting, and abdominal discomfort, which are common with GLP-1 drugs. More seriously, experts worry about the impact of reduced food intake on growth, bone development, and overall nutrition during the crucial adolescent years. The risk of developing eating disorders or psychological dependency is another key consideration. By defining a narrow role for these drugs, the WHO is prioritizing long-term safety while the science continues to evolve.
Implications for Families in India
These global guidelines arrive at a pertinent time for India, where adolescent obesity is a growing health concern. With drugs like semaglutide becoming available, the WHO's 'lifestyle-first' message provides a crucial framework for doctors and families. The guidelines encourage a shift away from seeking a quick fix towards embracing a more holistic and sustainable approach to health. They empower parents and adolescents to focus on building healthy environments and habits, with medical interventions reserved for exceptional circumstances under strict supervision. The core message is that managing obesity is a long-term journey focused on well-being, not just a number on a scale, a principle that will be vital in shaping pediatric care across the country.
